These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 26246143)
1. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia. Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298 [TBL] [Abstract][Full Text] [Related]
3. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486 [TBL] [Abstract][Full Text] [Related]
4. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis. Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509 [TBL] [Abstract][Full Text] [Related]
5. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL. Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814 [TBL] [Abstract][Full Text] [Related]
10. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088 [TBL] [Abstract][Full Text] [Related]
12. KIR2DS3 is associated with protection against acute myeloid leukemia. Shahsavar F; Tajik N; Entezami KZ; Fallah Radjabzadeh M; Asadifar B; Alimoghaddam K; Ostadali Dahaghi M; Jalali A; Ghashghaie A; Ghavamzadeh A Iran J Immunol; 2010 Mar; 7(1):8-17. PubMed ID: 20371915 [TBL] [Abstract][Full Text] [Related]
13. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Dulphy N; Chrétien AS; Khaznadar Z; Fauriat C; Nanbakhsh A; Caignard A; Chouaib S; Olive D; Toubert A Front Immunol; 2016; 7():94. PubMed ID: 27014273 [TBL] [Abstract][Full Text] [Related]
14. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Munker R; Andreeff M Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D Front Immunol; 2018; 9():977. PubMed ID: 29780393 [TBL] [Abstract][Full Text] [Related]
16. Natural killer cells adhere to bone marrow fibroblasts and inhibit adhesion of acute myeloid leukemia cells. Bendall LJ; Kortlepel K; Bradstock KF; Gottlieb DJ Leukemia; 1995 Jun; 9(6):999-1005. PubMed ID: 7596192 [TBL] [Abstract][Full Text] [Related]
17. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance. Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893 [TBL] [Abstract][Full Text] [Related]
18. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031 [TBL] [Abstract][Full Text] [Related]
19. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224 [TBL] [Abstract][Full Text] [Related]
20. Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients. Pittari G; Fregni G; Roguet L; Garcia A; Vataire AL; Wittnebel S; Amsellem S; Chouaib S; Bourhis JH; Caignard A Bone Marrow Transplant; 2010 May; 45(5):862-71. PubMed ID: 19802033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]